Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00648440 | Food Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg | PHASE1 | COMPLETED | 36 | — | — | Oct 1, 2002 | Nov 1, 2002 | Apr 24, 2024 | 1 | United States |
| NCT00650364 | Fasting Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg | PHASE1 | COMPLETED | 38 | — | — | Aug 1, 2002 | Sep 1, 2002 | Apr 24, 2024 | 1 | United States |
| NCT00650013 | Fed Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg | PHASE1 | COMPLETED | 23 | — | — | Jul 1, 2002 | Aug 1, 2002 | Apr 23, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Midodrine HCl Tablets 5 mg |
| 2 | ACTIVE_COMPARATOR | ProAmatine® Tablets 5 mg |
| Name | Type | Description |
|---|---|---|
| Midodrine HCl Tablets 5 mg | DRUG | 5mg, single dose fed |
| ProAmatine® Tablets 5 mg | DRUG | 5mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum Beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to the start of the study and the evening prior ...